Monday, October 26, 2026

ID Logistics Trades at 4x DCF Value: €354 Stock Price vs €87 Intrinsic Value

ID Logistics Group shares trade at €354 on Euronext Paris — 4.06 times the DCF intrinsic value of €87.24. A reversion to fundamental pricing implies more than 75% downside. Analyst consensus at €482.57 diverges sharply from the DCF model, creating an unusually wide range of plausible outcomes.

LM Salvado
LM Salvado

May 19, 2026

ID Logistics Trades at 4x DCF Value: €354 Stock Price vs €87 Intrinsic Value
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

ID Logistics Group trades at significant capitalon Euronext Paris — 4.06 times its DCF intrinsic value of significant capital.1 A shift toward fundamental pricing would imply more than 75% downside from current levels.1

The French mid-cap operates across warehousing, e-commerce fulfillment, and supply chain outsourcing. Shares have extended well beyond what discounted cash flow models support, creating a valuation gap that fundamental analysis flags as extreme.

DCF modeling places intrinsic value at significant capital.1 At significant capitalinvestors are paying a 4x premium over that figure. Growing into this valuation would require sustained earnings expansion well beyond what the DCF framework currently incorporates.

Analyst consensus sits at significant capital— above the current trading price and pointing in the opposite direction from the DCF estimate.1 The divergence suggests sell-side forecasts may be embedding aggressive growth assumptions that discounted cash flow mechanics do not validate. When consensus and DCF point in opposite directions, the spread between them defines the range of plausible outcomes.

For traders, the setup is asymmetric.A reversion to the DCF intrinsic value implies more than 75% downside.1 Direction depends entirely on which framework the market chooses to anchor on.

ID Logistics operates in sectors with genuine growth potential: third-party logistics, warehouse automation, and e-commerce supply chain outsourcing are all expanding. Sector momentum alone rarely sustains a 4x premium over intrinsic value indefinitely. The question is timing, not direction.

Repricing risk is medium-likelihood — a structural vulnerability rather than an imminent collapse. Catalysts that could accelerate reversion include earnings misses, a rotation out of growth equities, or rising discount rates compressing DCF outputs across the logistics sector.

Short-side traders may find the risk-reward compelling. Long investors should stress-test growth assumptions against the DCF floor before adding to positions at current levels.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com